PET-CT imaging
Overview
Hybrid positron emission tomography combined with computed tomography (PET-CT), providing co-registered functional (metabolic) and anatomical imaging in a single acquisition. In oncology, the most common tracer is 18F-FDG (see fdg-pet-ct), but other tracers are used for specific targets. PET-CT is used for initial staging, restaging, and treatment response assessment in head and neck cancer and other solid tumors.
Used by
- PMID:30179230 — whole-body PET-CT acquired in 212/215 (98.6%) HNSCC patients at baseline and 213/215 (99.1%) post-treatment in the MD Anderson HNSCC imaging archive (tcia-hnscc); scanners included GE Discovery RX, Discovery ST, and Discovery STE; archive includes 433,384 DICOM files spanning diagnostic CT, PET-CT, MRI, simulation CT, RTSTRUCT, RTPLAN, and RTDOSE PMID:30179230.
- Pre-operative PET/CT reviewed for 92/96 TRACERx patients; FDG avidity (tumor-to-background ratio) predicted pre-operative ctDNA detection by ROC AUC 0.84 (P<0.001) PMID:28445469
Notes
- Patient eligibility for the HNSCC archive required whole-body PET-CT or abdominal CT performed at MD Anderson both before and after RT; this selection criteria biases the cohort toward patients with full institutional follow-up PMID:30179230.
- The pre/post-treatment PET-CT pairs enable imaging-based response assessment and support body-composition measurement at L3 vertebra level (see body-composition-ct) PMID:30179230.
Sources
This page was processed by entity-page-writer on 2026-04-15. - PMID:28445469
This page was processed by wiki-cli on 2026-05-15.